A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world.
Idiopathic pulmonary fibrosis (IPF)
anti-fibrotic drug
nintedanib
severity
tolerability
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
ppublish
Résumé
Nintedanib is a tyrosine kinase inhibitor that has been shown to suppress progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib for IPF has been previously proven in the INPULSIS We retrospectively investigated medical records of 8 patients with severe IPF and 14 patients with non-severe IPF who had been treated with nintedanib. The criteria to define severe IPF were forced vital capacity (FVC) of <50% predicted and/or diffusing capacity of the lung for carbon monoxide/alveolar volume (D The median treatment period was 578.5 days. The most frequent adverse event was diarrhea (73%). Only 2 patients required permanent discontinuation of nintedanib due to adverse events. There was no difference in incidence or severity of adverse events or incidence of permanent or temporary discontinuation of nintedanib in between severe and non-severe IPF groups. Among subjects, decline in FVC during 6 months post-nintedanib treatment were significantly lower than prior to treatment, but change in serum KL-6 level showed no significant difference between these 2 timepoints. Our study showed that nintedanib was tolerable for IPF patients who would not have been eligible for entry into previous clinical trials due to low pulmonary function. Although therapeutic strategy for severe IPF should be planned carefully, initiation of nintedanib treatment should not be dismissed solely for reasons of low pulmonary function.
Sections du résumé
BACKGROUND
BACKGROUND
Nintedanib is a tyrosine kinase inhibitor that has been shown to suppress progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib for IPF has been previously proven in the INPULSIS
METHODS
METHODS
We retrospectively investigated medical records of 8 patients with severe IPF and 14 patients with non-severe IPF who had been treated with nintedanib. The criteria to define severe IPF were forced vital capacity (FVC) of <50% predicted and/or diffusing capacity of the lung for carbon monoxide/alveolar volume (D
RESULTS
RESULTS
The median treatment period was 578.5 days. The most frequent adverse event was diarrhea (73%). Only 2 patients required permanent discontinuation of nintedanib due to adverse events. There was no difference in incidence or severity of adverse events or incidence of permanent or temporary discontinuation of nintedanib in between severe and non-severe IPF groups. Among subjects, decline in FVC during 6 months post-nintedanib treatment were significantly lower than prior to treatment, but change in serum KL-6 level showed no significant difference between these 2 timepoints.
CONCLUSIONS
CONCLUSIONS
Our study showed that nintedanib was tolerable for IPF patients who would not have been eligible for entry into previous clinical trials due to low pulmonary function. Although therapeutic strategy for severe IPF should be planned carefully, initiation of nintedanib treatment should not be dismissed solely for reasons of low pulmonary function.
Identifiants
pubmed: 31355229
doi: 10.21037/atm.2019.05.33
pii: atm-07-12-262
pmc: PMC6614312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
262Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Am J Respir Crit Care Med. 2001 Jul 1;164(1):103-8
pubmed: 11435247
Am J Respir Crit Care Med. 2003 Sep 1;168(5):531-7
pubmed: 12791580
Chest. 2005 Jan;127(1):171-7
pubmed: 15653980
Thorax. 2005 Apr;60(4):270-3
pubmed: 15790978
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57
pubmed: 18337594
Chest. 2009 Nov;136(5):1364-1370
pubmed: 19892675
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
Respir Investig. 2012 Mar;50(1):3-13
pubmed: 22554854
Respir Med. 2013 Sep;107(9):1431-7
pubmed: 23849626
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Chest. 2014 Apr;145(4):723-728
pubmed: 24114524
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2014 Oct 1;190(7):773-9
pubmed: 25162152
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
Respir Res. 2015 Sep 24;16:116
pubmed: 26400368
Lung. 2016 Oct;194(5):739-43
pubmed: 27377558
Sci Rep. 2017 Sep 7;7(1):10811
pubmed: 28883482
Respiration. 2018;95(5):301-309
pubmed: 29490307
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
N Engl J Med. 2018 Nov 1;379(18):1722-1731
pubmed: 30220235
Am Rev Respir Dis. 1993 Sep;148(3):637-42
pubmed: 8368634
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1680-4
pubmed: 9817725